Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913884 | 0.84 | TPMT (0.35) | — | |
| SCHEMBL2039219 | 0.84 | PARP1 (0.38) | PARP1POLBHCAR2CES2CES1 | |
| SCHEMBL985711 | 0.84 | PARP1 (0.38) | PARP1POLBHCAR2CES2CES1 | |
| SCHEMBL28699581 | 0.84 | TPMT (0.35) | — | |
| SCHEMBL200827 | 0.80 | TPMT (0.48) | POLBHCAR2 | |
| SCHEMBL29528960 | 0.80 | TPMT (0.48) | POLBHCAR2 | |
| SCHEMBL200586 | 0.78 | CA5A (0.43) | PARP1POLBHCAR2NOTUM | |
| SCHEMBL5223135 | 0.78 | PARP1 (0.50) | PARP1POLB | |
| SCHEMBL6133362 | 0.76 | POLB (0.47) | POLBHCAR2 | |
| SCHEMBL986020 | 0.76 | TPMT (0.44) | PARP1POLBHCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018148721-A1 | HIGHLY SELECTIVE AKR1C3 INHIBITORS AND METHODS OF USE THEREOF | TEXAS TECH UNIVERSITY SYSTEM (US) | 2018-08-16 | — | — | WO | disclosed |
| EP-2246370-B1 | POLYMER COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO LTD (KR) | 2017-04-12 | — | — | EP | disclosed |
| US-8617722-B2 | Polymer compound and organic electroluminescence element using the same | SHOWA DENKO K.K. (JP) | 2013-12-31 | — | — | US | disclosed |
| CN-102317328-A | Polymer compound and organic electroluminescent element using the same | SHOWA DENKO KK (JP) | 2012-01-11 | — | — | CN | disclosed |
| US-20100327738-A1 | POLYMER COMPOUND AND ORGANIC ELECTROLUMINESCENCE ELEMENT USING THE SAME | SHOWA DENKO K.K. (JP) | 2010-12-30 | — | — | US | disclosed |
| EP-2246370-A1 | POLYMER COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SHOWA DENKO K.K. (JP) | 2010-11-03 | — | — | EP | disclosed |
| EP-1636221-B1 | 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists | ALBIREO AB (SE) | 2009-08-12 | — | — | EP | disclosed |
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| EP-1379525-B1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMA INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| CN-1805957-A | Azetidine compounds | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | CN | disclosed |
| EP-1679313-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1636221-A2 | NEW AZETIDINE COMPOUNDS | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2004110344-A2 | NEW AZETIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-12-23 | — | — | WO | disclosed |
| EP-1379525-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6660753-B2 | For therapy of stroke, head trauma, anoxic injury, ischemic injury, hypoglycemia, epilepsy, pain, migraine headaches, Parkinson's disease, senile dementia, Huntington's Chorea, anxiety, and Alzheimer's disease | NPS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154027-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PARP1 4043/4885POLB 3928/4885HCAR2 62/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | PARP1 4043/4885POLB 3928/4885HCAR2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.